Cargando…
Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma
Isatuximab is a newly approved targeted therapy for the treatment of patients with advanced multiple myeloma. Infusion reactions happen often with targeted therapies like isatuximab and can be severe or even life-threatening. However, ocular infusion reactions are rare. We report a 75-year-old femal...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973249/ https://www.ncbi.nlm.nih.gov/pubmed/35371888 http://dx.doi.org/10.7759/cureus.22764 |